How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?

Abstract Several randomized controlled trials of anti-estrogens, such as tamoxifen and aromatase inhibitors, have demonstrated up to a 50–65% decrease in breast cancerincidence among high-risk women. Approximately 15% of women, age 35–79 years, in the U.S. meet criteria for breast cancer preventive...

Full description

Saved in:
Bibliographic Details
Main Authors: Katherine D. Crew, Kathy S. Albain, Dawn L. Hershman, Joseph M. Unger, Shelly S. Lo
Format: article
Language:EN
Published: Nature Portfolio 2017
Subjects:
Online Access:https://doaj.org/article/9e9b0c4255f248ec9c7a12bc8d55c04e
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items